医学と薬学　72/7　2015年7月号

出版社： 自然科学社
発行日： 2015-06-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： 認知症の診断と治療update
電子書籍版： 2015-06-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,100 円(税込)

購入する

目次

  • 医学と薬学　72/7　2015年7月号

    ―目次―

    特集　認知症の診断と治療update

    序文
    アルツハイマー型認知症の診断と治療
    レビー小体型認知症/認知症を伴うパーキンソン病の診断と治療
    前頭側頭葉変性症の診断と治療
    血管性認知障害の診断と治療
    認知症の非薬物療法
    認知症の危険因子とそのマネジメント

    研究
    　夜間頻尿に対するイミダフェナシンおよびソリフェナシンの
    　　有効性および安全性の無作為比較臨床試験
    　Soy peptides exhibit superior absorption compared with
    　　 protein beverages

    臨床報告
    　急性冠症候群患者に対するランジオロールの超急性期投与

    Diagnosis
    　COBAS8000を用いたエクルーシス試薬ProGRPの基礎的検討
    　乳癌抗原・BCA225測定試薬「ステイシアMEBLuxTMテストBCA225」
    　　の基礎的検討

    Cosmetic
    　二重盲検ランダム化比較試験による
    　　レスベラトロール経口摂取の肌改善効果

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 認知症の診断と治療update】

P.1162 掲載の参考文献
1) 厚生労働省科学研究補助金, 認知症対策総合研究事業, 平成23年～24年総合研究報告書.
 
2) 認知症疾患治療ガイドライン作成合同委員会 : 認知症疾患治療ガイドライン2010, 医学書院, 東京, 2010.
 
3) Miyamoto T, Miyamoto M, Iwanami M et al : The REM sleep behavior disorder screening questionnaire : validation study of a Japanese version. Sleep Med 10 : 1151-1154, 2009.
PubMed
4) Fujiwara Y, Suzuki H, Yasunaga M et al : Brief screening tool for mild cognitive impairment in older Japanese : validation of the Japanese version of the Montreal Cognitive Assessment. Geriatr Gerontol Int 10 : 225-232, 2010.
PubMed
5) 松田博史 : 早期アルツハイマー型認知症診断支援システムVSRAD(R)について. 日本放射線技術学会雑誌 62 : 1066-1072, 2006.
 
6) Matsuda H, Mizumura S, Nagao T et al : Automated discrimination between very early Alzheimer disease and controls using an easy Z-score imaging system for multicenter brain perfusion single-photon emission tomography. AJNR Am J Neuroradiol 28 : 731-736, 2007.
PubMed
7) 認知症疾患治療ガイドライン作成合同委員会 : 認知症疾患治療ガイドライン2010 コンパクト版 2012, 医学書院, 東京, 2012.
 
8) Hansen RA, Gartlehner G, Webb AP et al : Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease : a systematic review and meta-analysis. Clin Interv Aging 3 : 211-225, 2008.
PubMed
9) Winblad B, Grossberg G, Frolich L et al : IDEAL : a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 69 (Suppl 1) : S14-22, 2007.
 
10) 高橋長秀, 高橋昌義, 朱年亮他 : ドネペジル治療で効果不十分であったアルツハイマー型認知症に対するガランタミン臭化塩素酸塩の有効性および安全性の検討. 老年精神医学雑誌 25 : 70-86, 2014.
 
11) Gauthier S, Emre M, Farlow MR et al : Strategies for continued successful treatment of Alzheimer's disease : switching cholinesterase inhibitors. Curr Med Res Opin 19 : 707-714, 2003.
 
12) 中村祐, 本間昭, 北村伸他 : 新規NMDA受容体拮抗剤であるメマンチン塩酸塩の中等度から高度アルツハイマー型認知症に対する第III相試験, 有効性および安全性の検討. 老年精神医学雑誌 22 : 464-473, 2011.
Medical*Online
13) 認知症, 特にBPSDへの適切な薬物使用に関するガイドライン作成に関する研究班 : かかりつけ医のためのBPSDに対応する向精神薬使用ガイドライン. www.mhlw.go.jp/file.jsp?id=130724
 
P.1169 掲載の参考文献
1) McKeith IG, Dickson DW, Lowe J et al : Diagnosis and management of dementia with Lewy bodies : third report of the DLB Consortium. Neurology 65 : 1863-1872, 2005.
PubMed
2) Yoshita M, Arai H, Arai H et al : Diagnostic Accuracy of 123IMeta-Iodobenzylguanidine Myocardial Scintigraphy in Dementia with Lewy Bodies : A Multicenter Study. PLoS ONE 10 (3) : e0120540. doi : 10.1371/journal.pone.0120540, 2015.
 
3) 長濱康弘 : レビー小体型認知症の認知機能障害. 老年精神医学雑誌 17 : 400-407, 2006.
Medical*Online
4) 長濱康弘 : レビー小体型認知症 (DLB) における認知機能障害に対する薬物療法. 精神科治療学 28 : 1597-1602, 2013.
 
5) Ferman TJ, Smith GE, Boeve BF et al : DLB fluctuations. Specific features that reliably differentiate DLB from AD and normal aging. Neurology 62 : 181-187, 2004.
PubMed
6) 長濱康弘, 翁朋子, 鈴木則夫他 : レビー小体型痴呆の臨床症状と認知機能の特徴. 老年精神医学雑誌 15 : 759-766, 2004.
Medical*Online
7) Nagahama Y, Okina T, Suzuki N et al : Classification of psychotic symptoms in dementia with Lewy bodies. Am J Geriatr Psychiatry 15 : 961-967, 2007.
PubMed
8) Nagahama Y, Okina T, Suzuki N et al : Neural correlates of psychotic symptoms in dementia with Lewy bodies. Brain 133 : 557-567, 2010.
PubMed
9) 長濱康弘 : BPSDの初期症状. 老年精神医学雑誌 26 (増刊-1) : 40-46, 2015.
 
10) Rolinski M, Fox C, Maidment I et al : Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012 : Issue 3, 2012.
 
11) Emre M, Aarsland D, Albanese A et al : Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351 : 2509-2518, 2004.
PubMed
12) McKeith I, Del Ser T, Spano P et al : Efficacy of rivastigmine in dementia with Lewy bodies : a randomised, double-blind, placebo-controlled international study. Lancet 356 : 2031-2036, 2000.
 
13) Mori E, Ikeda M, Kosaka K : Donepezil for dementia with Lewy bodies : a randomized, placebo-controlled trial. Ann Neurol 72 : 41-52, 2012.
PubMed
14) Dubois B, Tolosa E, Katzenschlager R et al : Donepezil in Parkinson's disease dementia : a randomized, double-blind efficacy and safety study. Mov Disord 27 : 1230-1238, 2012.
PubMed
15) Aarsland D, Ballard C, Walker Z et al : Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies : a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8 : 613-618, 2009.
PubMed
16) Emre M, Tsolaki M, Bonuccelli U et al : Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies : a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9 : 969-977, 2010.
PubMed
17) Dubois B, Tolosa E, Katzenschlager R et al : Donepezil in Parkinson's disease dementia : a randomized, double-blind efficacy and safety study. Mov Disord 27 : 1230-1238, 2012.
PubMed
18) Edwards K, Royall D, Hershey L et al : Efficacy and safety of galantamine in patients with dementia with Lewy bodies : a 24-week open-label study. Dement Geriatr Cogn Disord 23 (6) : 401-405, 2007.
PubMed
19) Kurlan R, Cummings J, Raman R et al : Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 68 : 1356-1363, 2007.
PubMed
20) Fernandez HH, Trieschmann ME, Burke MA et al : Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry 63 : 513-515, 2002.
PubMed
21) Cummings JL, Street J, Masterman D et al : Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dement Geriatr Cogn Disord 13 : 67-73, 2002.
PubMed
22) Culo S, Mulsant BH, Rosen J et al : Treating neuropsychiatric symptoms in dementia with Lewy bodies : a randomized controlled-trial. Alzheimer Dis Assoc Disord 24 (4) : 360-364, 2010.
PubMed
23) Iwasaki K, Kosaka K, Mori H et al : Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine. Psychogeriatrics 12 (4) : 235-241, 2012.
PubMed
24) Devos D, Dujardin K, Poirot I et al : Comparison of desipramine and citalopram treatments for depression in Parkinson's disease : a double-blind, randomized, placebo-controlled study. Mov Disord 23 (6) : 850-857, 2008.
PubMed
25) Richard IH, McDermott MP, Kurlan R et al : A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 78 (16) : 1229-1236, 2012.
PubMed
26) Larsson V, Aarsland D, Ballard C et al : The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry 25 (10) : 1030-1038, 2010.
PubMed
P.1182 掲載の参考文献
1) Neary D, Snowden JS, Gustafson L et al : Frontotemporal lobar degeneration : a consensus on clinical diagnostic criteria. Neurology 51 : 1546-1554 ,1998.
 
2) Yatabe Y, Hashimoto M, Kaneda K et al : Neuropsychiatric symptoms of progressive supranuclear palsy in a dementia clinic. Psychog eriatrics 11 : 54-59, 2011.
 
3) Mendez MF, Shapira JS, Miller BL : Stereotypical movements and frontotemporal dementia. Mov Disord 20 : 742-745, 2005.
PubMed
4) 森悦朗 : 前頭前野病変による行為障害・行動障害. 神経心理 12 : 106-113, 1996.
 
5) Mendez MF, Cummings JL : Dementia : A clinical approach, 3rd ed., ed. by Mendez MF, Cummings JL, Butterworth-Heinemann, Boston, 2003.
 
6) Shinagawa S, Ikeda M, Fukuhara R et al : Initial symptoms in frontotemporal dementia and semantic dementia compared with Alzheimer's disease. Dement Geriatr Cogn Disord 21 : 74-80, 2006.
PubMed
7) Rascovsky K, Salmon DP, Lipton AM et al : Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 65 : 397-403, 2005.
PubMed
8) Hornberger M, Piguet O, Graham AJ et al : How preserved is episodic memory in behavioral variant frontotemporal dementia? Neurology 74 (6) : 472-479. 2010.
PubMed
9) Kitagaki H et al : Alteration of white matter MR signal intensity in frontotemporal dementia. Am J Neuroradiol 18 : 367-378, 1997.
PubMed
10) Coppola G, Karydas A, Rademakers R et al : Gene expression study on peripheral blood identifies progranulin mutations. Ann Neurol 64 : 92-96, 2008.
 
11) Rascovsky K, Hodges JR, Knopman D et al : Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134 : 2456-2477, 2011.
PubMed
12) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders 4th edition, Text Revision. American Psychiatric Association, Washington, DC, 2000.
 
13) 高橋三郎, 大野裕, 染矢俊幸訳 : DSM-IV-TR精神疾患の診断・統計マニュアル (新訂版). 医学書院, 東京, 2004
 
14) Mendez MF, Shapira JS, Woods RJ et al : Psychotic symptoms in frontotemporal dementia : prevalence and review. Dement Geriatr Cogn Disord 25 : 206-211, 2008.
PubMed
15) Lagier-Tourenne C, Baughn M, Rigo F et al : Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc Natl Acad Sci USA 110 : E4530-E4539, 2013.
 
16) Yanamandra K, Jiang H, Mahan TE et al : Antitau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol 2 : 278-288, 2015.
PubMed
17) Fukuhara R, Ghosh A, Fuh JL et al : Family history of frontotemporal lobar degeneration in Asia-an international multi-center research. Int Psychogeriatr 26 : 1967-1971, 2014.
PubMed
18) Huey ED, Putnam KT, Grafman J : A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 66 : 17-22, 2006.
PubMed
19) Engelborghs S, Vloeberghs E, Maertens K et al : Evidence for an association between the CSF HVA : 5-HIAA ratio and aggressiveness in frontotemporal dementia but not in Alzheimer's disease. J Neurol Neurosurg Psychiatry 75 : 1080, 2004.
 
20) Yang Y, Schmitt HP : Frontotemporal dementia : evidence for impairment of ascending serotoninergic but not noradrenergic innervation. Immunocytochemical and quantitative study using a graph method. Acta Neuropathol 101 : 256-270, 2001.
 
21) Sparks D, Markesbery WR : Altered serotonergic and cholinergic synaptic markers in Pick's disease. Arch Neurol 48 : 796-799, 1991.
PubMed
22) Swartz JR, Miller BL, Lesser IM et al : Frontotemporal dementia : treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 58 : 212-216, 1997.
PubMed
23) Ikeda M, Shigenobu K, Fukuhara R et al : Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord 17 : 117-121, 2004.
PubMed
24) Moretti R, Torre P, Antonello RM et al : Frontotemporal dementia : paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol 49 : 13-19, 2003.
PubMed
25) Deakin JB, Rahman S, Nestor PJ et al : Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia : a double-blind randomized controlled trial. Psychopharmacology (Berl) 172 : 400-408, 2004.
 
26) Mendez MF, Shapira JS, Miller BL : Stereotypical movements and frontotemporal dementia. Mov Disord 20 : 742-745, 2005.
PubMed
27) Herrmann N, Black SE, Chow T et al : Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry 20 : 789-797, 2012.
PubMed
28) Lebert F, Stekke W, Hasenbroekx C et al : Frontotemporal dementia : a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 17 : 355-359, 2004.
PubMed
29) Karageorgiou E, Miller BL : Frontotemporal Lobar Degeneration : A Clinical Approach. Semin Neurol 34 : 189-201, 2014.
PubMed
30) Moretti, R, Torre P, Antonello RM et al : Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias : a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen 18 : 205-214, 2003.
PubMed
31) Curtis RC, Resch DS : Case of pick's central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J Clin Psychopharmacol 20 : 384-385, 2000.
 
32) Fellgiebel A, Muller MJ, Hiemke C et al : Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry 8 : 123-126, 2007.
 
33) Moretti R, Torre P, Antonello RM et al : Rivastigmine in frontotemporal dementia : an open-label study. Drugs Aging 21 : 931-937, 2004.
PubMed
34) Mendez MF, Shapira JS, McMurtray A : Preliminary findings : behavioral worsening on donepezil in patients with frontotemporal dementia.Am J Geriatr Psychiatry 15 : 84-87, 2007.
PubMed
35) Kertesz A, Morlog D, Light M et al : Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord 25 : 178-185, 2008.
PubMed
36) Diehl-Schmid J, Forstl H, Perneczky R et al : A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry 23 : 754-759, 2008.
PubMed
37) Boxer AL, Lipton AM, Womack K et al : An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 23 : 211-217, 2009.
PubMed
38) Boxer AL, Knopman DS, Kaufer DI et al : Memantine in patients with frontotemporal lobar degeneration : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 12 : 149-156, 2013.
PubMed
39) Ikeda M : Fronto-temporal dementia. In Therapeutic strategies in dementia (editors, Ritchie CW, Ames D et al), pp.287-299, Clinical Publishing, Oxford, 2007.
 
40) 品川俊一郎, 矢田部裕介, 繁信和恵他 : 本邦におけるFTDに対するoff-label処方の実態について. Dementia Japan 29 : 78-85, 2015.
 
P.1192 掲載の参考文献
1) Ikejima C, Ikeda M, Hashimoto M et al : Multicenter population-based study on the prevalence of early onset dementia in Japan : vascular dementia as its prominent cause. Psychiatry Clin Neurosci 68 (3) : 216-224, 2014.
 
2) Pohjasvaara T, Mantyla R, Ylikoski R et al : Comparison of different clinical criteria (DSMIII, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neuro. Stroke 31 (12) : 2952-2957, 2000.
 
3) Gold G, Bouras C, Canuto A et al : Clinicopathological validation study of four sets of clinical criteria for vascular dementia. Am J Psychiatry 159 (1) : 82-87, 2002.
PubMed
4) Sachdev P, Kalaria R, O'Brien J et al : Diagnostic Criteria for Vascular Cognitive Disorders : A VASCOG Statement. Alzheimer Dis Assoc Disord, 2014.
PubMed
5) Kalaria RN, Ballard C : Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 13 (Suppl 3) : S115-S123, 1999.
 
6) Snowdon DA, Greiner LH, Mortimer JA et al : Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277 (10) : 813-817, 1997.
PubMed
7) Kalaria RN, Akinyemi R, Ihara M : Does vascular pathology contribute to Alzheimer changes? J Neurol Sci 322 (1-2) : 141-147.
 
8) Rockwood K, Wentzel C, Hachinski V et al : Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology 54 (2) : 447-451, 2000.
PubMed
9) Hachinski V, Iadecola C, Petersen RC et al : National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 37 (9) : 2220-2241, 2006.
PubMed
10) 猪原匡史 : Vascular cognitive impairment (VCI). 最新・脳血管疾患Update-研究と臨床の最前線, 脳血管疾患の診断の最前線. 医学のあゆみ 231 (5) : 452-457, 2009.
 
11) Gorelick PB, Scuteri A, Black SE et al : Vascular contributions to cognitive impairment and dementia : a statement for healthcare professionals from the american heart association /american stroke association. Stroke 42 (9) : 2672-2713, 2011.
PubMed
12) Ihara M, Kalaria RN : Understanding and preventing the development of post-stroke dementia. Expert Rev Neurother 14 (9) : 1067-1077, 2014.
PubMed
13) Hachinski VC, Lassen NA, Marshall J : Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet 2 (7874) : 207-210, 1974.
PubMed
14) 猪原匡史, 冨本秀和, 福山秀直 : 脳血管性痴呆の画像所見. インターベンション時代の脳卒中学 (改訂第2版) 超急性期から再発予防まで, 脳血管障害各論, 脳血管性痴呆 (VD). 日本臨牀 64 (増刊8 インターベンション時代の脳卒中学〔下〕) : 787-791, 2006.
 
15) Jellinger K, Neumayer E : Binswanger's progressive subcortical vascular encephalopathy. A clinico-neuropathological study. Arch Psychiatr Nervenkr 205 : 523-554, 1964.
PubMed
16) Andin U, Gustafson L, Passant U et al : A clinico-pathological study of heart and brain lesions in vascular dementia. Dement Geriatr Cogn Disord 19 (4) : 222-228, 2005.
 
17) Bowler JV : Modern concept of vascular cognitive impairment. Br Med Bull 83 : 291-305, 2007.
PubMed
18) Ihara M, Polvikoski TM, Hall R et al : Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer's disease, and dementia with Lewy bodies. Acta Neuropathol 119 (5) : 579-589, 2010.
PubMed
19) Ihara M, Tomimoto H, Ishizu K et al : Decrease in cortical benzodiazepine receptors in symptomatic patients with leukoaraiosis : a positron emission tomography study. Stroke 35 (4) : 942-947, 2004.
PubMed
20) Cordonnier C, van der Flier WM, Sluimer JD et al : Prevalence and severity of microbleeds in a memory clinic setting. Neurology 66 (9) : 1356-1360, 2006.
 
21) Yamamoto Y, Ihara M, Tham C et al : Neuropathological correlates of temporal pole white matter hyperintensities in CADASIL. Stroke 40 (6) : 2004-2011, 2009.
PubMed
22) Hara K, Shiga A, Fukutake T et al : Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N Engl J Med 360 (17) : 1729-1739, 2009.
PubMed
23) Yamamoto Y, Craggs L, Baumann M et al : Review : molecular genetics and pathology of hereditary small vessel diseases of the brain. Neuropathol Appl Neurobiol 37 (1) : 94-113, 2011.
PubMed
24) Haffner C, Malik R, Dichgans M : Genetic factors in cerebral small vessel disease and their impact on stroke and dementia. J Cereb Blood Flow Metab, 2015.
 
25) Hachinski VC, Iliff LD, Zilhka E et al : Cerebral blood flow in dementia. Arch Neurol 32 (9) : 632-637, 1975.
PubMed
26) Okamoto Y, Yamamoto T, Kalaria RN et al : Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathol 123 (3) : 381-394, 2012.
PubMed
27) Okamoto Y, Ihara M, Fujita Y et al : Cortical microinfarcts in Alzheimer's disease and subcortical vascular dementia. Neuroreport 20 (11) : 990-996, 2009.
PubMed
28) Haglund M, Sjobeck M, Englund E : Severe cerebral amyloid angiopathy characterizes an underestimated variant of vascular dementia. Dement Geriatr Cogn Disord 18 (2) : 132-137, 2004.
PubMed
29) Selnes OA, Vinters HV : Vascular cognitive impairment. Nat Clin Pr Neurol 2 (10) : 538-547, 2006.
 
30) Smith EE, Greenberg SM : Beta-amyloid, blood vessels, and brain function. Stroke 40 (7) : 2601-2606, 2009.
PubMed
31) Meyer JS, Huang J, Chowdhury MH : MRI confirms mild cognitive impairments prodromal for Alzheimer's, vascular and Parkinson-Lewy body dementias. J Neurol Sci 257 (1-2) : 97-104, 2007.
 
32) Pendlebury ST, Cuthbertson FC, Welch SJ et al : Underestimation of cognitive impairment by mini-mental state examination versus the montreal cognitive assessment in patients with transient ischemic attack and stroke : a population-based study. Stroke 41 (6) : 1290-1293, 2010.
PubMed
33) Ihara M, Okamoto Y, Takahashi R : Suitability of the Montreal cognitive assessment versus the mini-mental state examination in detecting vascular cognitive impairment. J Stroke Cerebrovasc Dis 22 (6) : 737-741, 2013.
PubMed
34) Fotuhi M, Hachinski V, Whitehouse PJ : Changing perspectives regarding late-life dementia. Nat Rev Neurol 5 (12) : 649-658, 2009.
PubMed
35) Matthews FE, Brayne C, Lowe J et al : Epidemiological pathology of dementia : attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med 6 (11) : e1000180, 2009.
PubMed
36) Schneider JA, Arvanitakis Z, Bang W et al : Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69 (24) : 2197-2204, 2007.
PubMed
37) Viswanathan A, Rocca WA, Tzourio C : Vascular risk factors and dementia : how to move forward? Neurology 72 (4) : 368-374, 2009.
PubMed
38) Law MR, Morris JK, Wald NJ : Use of blood pressure lowering drugs in the prevention of cardiovascular disease : meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338 : b1665, 2009.
PubMed
39) Peters R, Beckett N, Forette F et al : Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG) : a double-blind, placebo controlled trial. Lancet Neurol 7 (8) : 683-689, 2008.
PubMed
40) 認知症疾患治療ガイドライン作成合同委員会 : 認知症疾患治療ガイドライン2010.
 
41) Snyder HM, Corriveau RA, Craft S et al : Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimer's Dement, 2014.
PubMed
P.1203 掲載の参考文献
1) Kurz AF, Leuchit S, Lautenschlanger NT : The clinical significance of cognition-focused interventions for cognitively impaired older adults : a systematic review of randomized controlled trials. Int Psychogeriatrics 11 : 1-12, 2011.
 
2) 佐藤正之 : 認知症の非薬物療法の現状と未来. 認知神経科学 15 (3) : 207-213, 2014.
 
3) Abbott RD, White LR, Ross GW et al : Walking and dementia in physically capable elderly men. JAMA 292 (12) : 1447-1453, 2004.
PubMed
4) Laurin D, Verreault R, Lindsay J et al : Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol 58 (3) : 498-504, 2001.
PubMed
5) Podewils LJ, Guallar E, Kuller LH et al : Physical activity, APOE genotype, and dementia risk : findings from the Cardiovascular Health Cognitive Study. Am J Epidemiol 161 (7) : 639-651, 2005.
PubMed
6) Ravaglia G, Forti P, Lucicesare A et al : Physical activity and dementia risk in the elderly : findings from a prospective Italian study. Neurology 70 (19 Pt 2) : 1786-1794, 2008.
 
7) Erickson KI, Voss MW, Prakash RS et al : Exercise training increases size of hippocampus and improves memory. PNAS 108 (7) : 3017-3022, 2011.
PubMed
8) Heyn P, Abreu BC, Ottenbacher KJ : The effects of exercise training on elderly persons with cognitive impairment and dementia : a meta-analysis. Arch Phys Med Rehabili 85 (10) : 1694-1704, 2004.
 
9) McDonnell MN, Smith AE, Mackintosh SF : Aerobic exercise to improve cognitive function in adults with neurological disorders : a systematic review. Arch Phys Med Rehabil 92 : 1044-1052, 2011.
PubMed
10) Ahlskog JE, Geda YE, Graff-Radford NR et al : Physical exercise as a preventive or disease-modifying treatment of dementia and brain aging. Mayo Clin Proc 86 (9) : 876-884, 2011.
PubMed
11) Erickson KI, Weinstein AM, Lopez OL : Physical activity, brain plasticity, and Alzheimer's disease. Arch Med Rehabil 43 : 615-621, 2012.
 
12) Lautenschlager NT, Cox K, Cyarto EV : The influence of exercise on brain aging and dementia. Biochimica et Biophysica Acta 1822 : 474-481, 2012.
PubMed
13) Woods B, Aguirre E, Spector AE et al : Cognitive stimulation to improve cognitive functioning in people with dementia (Review). Issue 2 : CD005562, 2012. DOI : 10.1002/14651858. CD005562. pub2.
 
14) Owen Am, Hampshire A, Grahn JA et al : Putting brain training to the test. Nature 465 (7299) : 775-778, 2010.
 
15) Haight BK, Gibson F, Michel Y : The northern Ireland life review/life storybook project for people with dementia. Alzheimer's & Dementia 2 : 56-58, 2006.
 
16) Onder G, Zanetti O, Giacobini E et al : Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease : radomised controlled trial. British J Psychiatry 187 : 450-455, 2005.
 
17) Livingston G, Johnston K, Katona C et al : Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 162 : 1996-2021, 2005.
 
18) Spector AE, Orrel M, Davies S et al : Reminiscence therapy for dementia (Review). Cochrane Library. Issue 2. Oxford : Update Software. 2004.
 
19) Forbes D, Culum I, Lischka CR et al : Light therapy for managing cognitive, sleep, functional, nehabioral, or psychiatric disturbances in dementia. Cochrane Database of Systematic Reviews, Issue 4. Art. No. : CD003946, 2009. DOI : 10.1002/14651858. CD003946. pub4.
 
20) Hermans, D, Htay, UH, Cooley, S : Non-pharmacological interventions for wandering of people with dementia in the domestic setting. The Cochrane Library, Issue 4 : CD005994, 2009. DOI : 10.1002/14651858. CD005994. pub2.
 
21) Ueda T, Suzukamo Y, Sato M et al : Effects of music therapy on behavioral and psychological symptoms of dementia : A systematic review and meta-analysis. Ageing Res Rev 12, 628-641, 2013.
PubMed
22) McDermott O, Crellin N, Ridder HM et al : Music therapy in dementia : a narrative synthesis systematic review. Int J Geriatr Psychiatry 28 (8) : 781-794, 2013.
PubMed
23) Livingston G, Kelly L, Lewis-Holmes E et al : Non-pharmacological interventions for agitation in dementia : systematic review of randomized controlled trials. Br J Psychiatry 205 : 436-442, 2014.
PubMed
24) Vink AC, Bruinsma MS, Scholten R JPM : Music therapy for people with dementia. The Cochrane Library, Issue 3 : CD003477, 2011. DOI : 10.1002/14651858. CD003477. pub2.
 
25) Vasionyte I, Madison G : Musical intervention for patients with dementia : a meta-analysis. J Clin Nursing 22, 1203-1216, 2013.
 
26) Fabre C, Chamari K, Mucci P et al : Improvement of cognitive function by mental and /or individualized aerobic training in healthy elderly subjects. Int J Sport Med 23 (6) : 415-421, 2002.
 
27) Oswald WD, Gunzelmann T, Rupprecht R et al : Differential effects of single versus combined cognitive and physical training with adults : the SimA study in a 5-year perspective. Eur J Ageing 3 : 179-192, 2006.
 
28) Shatil E : Does combined cognitive training and physical activity training enhance cognitive abilities more than either alone? A four-condition randomized controlled trial among healthy older adults. Front Aging Neurosci, 2013. doi : 10.3389/fnagi. 2013. 00008
 
29) Suzuki T, Shimada H, Makizako H et al : A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment PLOS ONE 8 (4) : e61483, 2013. Doi : 10.1371/journal. pone. 0061483
 
30) Satoh M, Ogawa J, Tokita T et al : The effects of physical exercise with music on cognitive function of elderly people : Mihama-Kiho project. PLOS ONE 9 (4) : e95230, 2014. doi : 10.1371/journal. pone. 0095230.
 
31) Mazzoni M, Moretti P, Pardossi L et al : A case of music imperceptions. J Neurol Neurosutg Psychiatry 56 : 322-324, 1993.
 
32) Sergent J, Zuck E, Terriah S et al : Distributed neural network underlying musical sight-reading and keyboard performance. Science 257 : 106-109, 1992.
PubMed
33) Platel H, Price C, Baron JC et al : The structural components of music perception. A functional anatomical study. Brain 120 : 229-243, 1997.
PubMed
34) Satoh M, Takeda K, Nagata K et al : Activated nrain regions in musicians during an ensemble : a PET study. Cog Brain Res 12 : 101-108, 2001.
 
35) Satoh M, Takeda K, Nagata K et al : The anterior portion of bilateral temporal lobes participates in music perception : a positron emission tomography study. Am J Neuroradiol 24 : 1843-1848, 2003.
PubMed
36) Brown S, Martinez M, Parsons LM : Passive music listening spontaneously engages limbic and paralimbic systems. Neuroreport 15 : 2033-2037, 2004.
PubMed
37) Satoh M, Takeda K, Nagata K et al : The lateral occipital complex is activated by melody with accompaniment : foreground and background segregation in auditory processing. J Behav Brain Sci 1 : 94-101, 2011. DOI : 10.4236/jbbs. 2011. 13013.
 
38) Satoh M, Nakase T, Nagata K et al : Musical anhedonia : selective loss of emotional experience in listening to music. Neurocase 17 : 410-417, 2011.
PubMed
39) Olazaran J, Reisberg B, Clare L : Nonpharmacological therapies in Alzheimer's disease : a systematic review of efficacy. Dement Geriatr Cogn Disord 30 : 161-178, 2010.
PubMed
P.1215 掲載の参考文献
1) Bendlin BB, Carlsson CM, Gleason CE et al : Midlife predictors of Alzheimer's disease. Maturitas 65 (2) : 131-137, 2010.
PubMed
2) Buchman AS, Boyle PA, Yu L et al : Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology 78 (17) : 1323-1329, 2012.
PubMed
3) James BD, RS Wilson, LL Barnes et al : Late-life social activity and cognitive decline in old age. J Int Neuropsychol Soc 17 (6) : 998-1005, 2011.
 
4) Barnes, DE, K Yaffe : The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 10 (9) : 819-828, 2011.
 
5) Leibson CL, Rocca WA, Hanson VA et al : Risk of dementia among persons with diabetes mellitus : a population-based cohort study. Am J Epidemiol 145 (4) : 301-308, 1997.
PubMed
6) Ott A, Stolk RP, van Harskamp F et al : Diabetes mellitus and the risk of dementia : The Rotterdam Study. Neurology 53 (9) : 1937-1942, 1999.
PubMed
7) Peila R, Rodriguez BL, Launer LJ et al : Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies : The Honolulu-Asia Aging Study. Diabetes 51 (4) : 1256-1262, 2002.
PubMed
8) Arvanitakis Z, Wilson RS, Bienias JL et a l : Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61 (5) : 661-666, 2004.
 
9) Matsuzaki T, Sasaki K, Tanizaki Y et al : Insulin resistance is associated with the pathology of Alzheimer disease : the Hisayama study. Neurology 75 (9) : 764-770, 2010.
PubMed
10) Ohara T, Doi Y, Ninomiya T e t al : Glucose tolerance status and risk of dementia in the community : the Hisayama study. Neurology 77 (12) : 1126-1134, 2011.
 
11) Craft S : Insulin resistance syndrome and Alzheimer's disease : age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 26 (Suppl 1) : 65-69, 2005.
 
12) Refolo LM, Malester B, LaFrancois J et al : Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7 (4) : 321-331, 2000.
 
13) Ho L, Qin W, Pompl PN et al : Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18 (7) : 902-904, 2004.
 
14) Julien C, Tremblay C, Phivilay A et al : High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model. Neurobiol Aging 31 (9) : 1516-1531, 2010.
PubMed
15) Fitz NF, Cronican A, Pham T et al : Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by highfat diet in APP23 mice. J Neurosci 30 (20) : 6862-6872, 2010.
PubMed
16) Maesako M, Uemura K, Kubota M et al : Exercise is more effective than diet control in preventing high fat diet-induced beta-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice. J Biol Chem 287 (27) : 23024-23033, 2012.
PubMed
17) Wang X, Zheng W, Xie JW et al : Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegener 5 : 46, 2010.
 
18) Devi L, Alldred MJ, Ginsberg SD et al : Mechanisms underlying insulin deficiency-induced acceleration of beta-amyloidosis in a mouse model of Alzheimer's disease. PLoS One 7 (3) : e32792, 2012.
 
19) Skoog I, Lernfelt B, Landahl S et al : 15-year longitudinal study of blood pressure and dementia. Lancet 347 (9009) : 1141-1145, 1996.
PubMed
20) Gottesman, RF, Schneider AL, Albert M et al : Midlife hypertension and 20-year cognitive change : the atherosclerosis risk in communities neurocognitive study. JAMA Neurol 71 (10) : 1218-1227, 2014.
PubMed
21) Qiu C, Winblad B, Fratiglioni L : The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 4 (8) : 487-499, 2005.
PubMed
22) Sperling RA, Aisen PS, Beckett LA et al : Toward defining the preclinical stages of Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (3) : 280-292, 2011.
PubMed
23) Bateman RJ, Xiong C, Benzinger TL et al : Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367 (9) : 795-804, 2012.
PubMed
24) Fratiglioni L, Launer LJ, Andersen K et al : Incidence of dementia and major subtypes in Europe : A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54 (11 Suppl 5) : S10-15, 2000.
 
25) Ferri CP, Prince M, Brayne C et al : Global prevalence of dementia : a Delphi consensus study. Lancet 366 (9503) : 2112-2117, 2005.
PubMed
26) Gao S, Hendrie HC, Hall KS et al : The relationships between age, sex, and the incidence of dementia and Alzheimer disease : a meta-analysis. Arch Gen Psychiatry 55 (9) : 809-815, 1998.
PubMed
27) Beydoun MA, Beydoun HA, Wang Y : Obesity and central obesity as risk factors for incident dementia and its subtypes : a systematic review and meta-analysis. Obes Rev 9 (3) : 204-218, 2008.
PubMed
28) Profenno LA, Porsteinsson AP, Faraone SV : Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 67 (6) : 505-512, 2010.
 
29) Kloppenborg RP, van den Berg E, Kappelle LJ et al : Diabetes and other vascular risk factors for dementia : which factor matters most? A systematic review. Eur J Pharmacol 585 (1) : 97-108, 2008.
PubMed
30) Luchsinger JA, Patel B, Tang MX et al : Measures of adiposity and dementia risk in elderly persons. Arch Neurol 64 (3) : 392-398, 2007.
PubMed
31) Xu WL, Atti AR, Gatz M et al : Midlife overweight and obesity increase late-life dementia risk : a population-based twin study. Neurology 76 (18) : 1568-1574, 2011.
 
32) Qizilbash N, Gregson J, Johnson ME et al : BMI and risk of dementia in two million people over two decades : a retrospective cohort study. Lancet Diabetes Endocrinol, 2015.
PubMed
33) Hamer M, Chida Y : Physical activity and risk of neurodegenerative disease : a systematic review of prospective evidence. Psychol Med 39 (1) : 3-11, 2009.
PubMed
34) Rolland Y, Abellan van Kan G, Vellas B : Physical activity and Alzheimer's disease : from prevention to therapeutic perspectives. J Am Med Dir Assoc 9 (6) : 390-405, 2008.
PubMed
35) Guthold R, Ono T, Strong KL et al : Worldwide variability in physical inactivity a 51-country survey. Am J Prev Med 34 (6) : 486-494, 2008.
PubMed
36) Kamat SM, Kamat AS, Grossberg GT : Dementia risk prediction : are we there yet? Clin Geriatr Med 26 (1) : 113-123, 2010.
PubMed
37) Varma VR, Chuang YF, Harris GC et al : Low-intensity daily walking activity is associated with hippocampal volume in older adults. Hippocampus 25 (5) : 605-615, 2015.
PubMed
38) Okamoto M, Hojo Y, Inoue K et al : Mild exercise increases dihydrotestosterone in hippocampus providing evidence for androgenic mediation of neurogenesis. Proc Natl Acad Sci USA 109 (32) : 13100-13105, 2012.
PubMed
39) Ohman H, Savikko N, Strandberg TE et al : Effect of physical exercise on cognitive performance in older adults with mild cognitive impairment or dementia : a systematic review. Dement Geriatr Cogn Disord 38 (5-6) : 347-365, 2014.
PubMed
40) Valenzuela MJ : Brain reserve and the prevention of dementia. Curr Opin Psychiatry 21 (3) : 296-302, 2008.
PubMed
41) Caamano-Isorna F, Corral M, Montes-Martinez A et al : Education and dementia : a meta-analytic study. Neuroepidemiology 26 (4) : 226-232, 2006.
PubMed
42) Sato N : Non-genetic risk factors for dementia. Rinsho Shinkeigaku 52 (11) : 968-970, 2012.
PubMed
43) Kubota M, Nagasaki M, Tokudome M et al : Mechanical horseback riding improves insulin sensitivity in elder diabetic patients. Diabetes Res Clin Pract 71 (2) : 124-130, 2006.
PubMed
44) Wing RR, Blair EH, Bononi P et al : Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 17 (1) : 30-36, 1994.
PubMed
45) Maesako M, Uemura K, Kubota M et al : Environmental enrichment ameliorated high-fat diet-induced Abeta deposition and memory deficit in APP transgenic mice. Neurobiol Aging 33 (5) : 1011 e11-23, 2012.
 
46) Kubota M, Koshinaka K, Kawata Y et al : Effects of continuous low-carbohydrate diet after longterm exercise on GLUT-4 protein content in rat skeletal muscle. Horm Metab Res 40 (1) : 24-28, 2008.
PubMed
47) Kashiwaya Y, Bergman C, Lee JH et al : A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease. Neurobiol Aging 34 (6) : 1530-1539, 2013.
 
48) Lautenschlager NT, Cox KL, Flicker L et al : Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease : a randomized trial. JAMA 300 (9) : 1027-1037, 2008.
PubMed
49) Oshida Y, Yamanouchi K, Hayamizu S et al : Long-term mild jogging increases insulin action despite no influence on body mass index or VO2 max. J Appl Physiol (1985) 66 (5) : 2206-2210, 1989.
PubMed
50) Baker LD, Frank LL, Foster-Schubert K et al : Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimer's disease. J Alzheimers Dis 22 (2) : 569-79, 2010.
PubMed
51) Liu-Ambrose T, Nagamatsu LS, Graf P et al : Resistance training and executive functions : a 12-month randomized controlled trial. Arch Intern Med 170 (2) : 170-178, 2010.
PubMed
52) Boyle PA, Buchman AS, Wilson RS et al : Association of muscle strength with the risk of Alzheimer disease and the rate of cognitive decline in community-dwelling older persons. Arch Neurol 66 (11) : 1339-1344, 2009.
PubMed
53) Miller JP, Pratley RE, Goldberg AP et al : Strength training increases insulin action in healthy 50- to 65-yr-old men. J Appl Physiol (1985) 77 (3) : 1122-1127, 1994.
 
54) Krisan AD, Collins DE, Crain AM et al : Resistance training enhances components of the insulin signaling cascade in normal and high-fat-fed rodent skeletal muscle. J Appl Physiol (1985) 96 (5) : 1691-1700, 2004.
PubMed
55) Takeda S, Sato N, Uchio-Yamada K et al : Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 107 (15) : 7036-7041, 2010.
 
56) Watson GS, Cholerton BA, Reger MA et al : Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone : a preliminary study. Am J Geriatr Psychiatry 13 (11) : 950-958, 2005.
PubMed
57) Cheng C, Lin CH, Tsai YW et al : Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis. J Gerontol A Biol Sci Med Sci 69 (10) : 1299-1305, 2014.
 
58) Efimova IY, Efimova NY, Triss SV et al : Brain perfusion and cognitive function changes in hypertensive patients. Hypertens Res 31 (4) : 673-678, 2008.
PubMed
59) Haag MD, Hofman A, Koudstaal PJ et al : Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80 (1) : 13-17, 2009.
PubMed
60) Woods B, Spector A, Jones C et al : Reminiscence therapy for dementia. Cochrane Database Syst Rev (2) : CD001120, 2005.
PubMed
61) Suzuki M, Tatsumi A, Otsuka T et al : Physical and psychological effects of 6-week tactile massage on elderly patients with severe dementia. Am J Alzheimers Dis Other Demen 25 (8) : 680-686, 2010.
PubMed
62) Green RC, Schneider LS, Amato DA et al : Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease : a randomized controlled trial. JAMA 302 (23) : 2557-2564, 2009.
PubMed

【研究】

P.1225 掲載の参考文献
1) 日本泌尿器科学会夜間頻尿診療ガイドライン作成委員会編 : 夜間頻尿診療ガイドライン. Blackwell Publishing, 東京, 2009.
 
2) Yamanishi T, Fuse M, Yamaguchi C, Uchiyama T, Kamai T, Kurokawa S, Morita T : Nocturia Quality-of-Life questionnaire is a useful tool to predict nocturia and a risk of falling in Japanese outpatients : A cross-sectional survey. Int J Urol 21 : 289-293, 2014.
 
3) Weiss JP, Blaivas JG, Jones M, Wang JT, Guan Z : Age related pathogenesis of nocturia in patients with overactive bladder. J Urol 178 : 548-551, 2007.
PubMed
4) Brubaker L, FitzGerald MP : Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int Urogynecol J Pelvic Floor Dysfunct. 18 : 737-741, 2007.
PubMed
5) Yokoyama O, Yamaguchi O, Kakizaki H, Itoh N, Yokota T, Okada H, Ishizuka O, Ozono S, Gotoh M, Sugiyama T, Seki N, Yoshida M, Yamada S : Efficacy of solifenacin on nocturia in Japanese patients with overactive bladder : impact on sleep evaluated by bladder diary. J Urol 186 : 170-174, 2011.
PubMed
6) Takeda M, Takahashi S, Nishizawa O, Gotoh M, Yoshida M : Imidafenacin, a Novel Anticholinergic, Significantly Improves Both Nocturia and Sleep Disorders in Oab Patients : Epoch (Evaluation of Anticholinergics in Patients with Overactive Bladder and Nocturia for Care Healthy) Study [Japanese]. Japanese Journal of Urological Surgery 22 : 53-60, 2009.
 
7) Takeda M, Takahashi S, Nishizawa O, Gotoh M, Yoshida M, Masumori N : Imidafenacin, a Novel Anticholinergic, Significantly Improves Nocturia, Sleep Disorders and Quality of Life in OAB Patients : Evolution (Evaluating the Value of nocturia-Quality Of Life questionnaire Utilization with Treatment of Imidafenacin for OAB patients suffering from Nocturia) Study [Japanese]. Japanese Journal of Urological Surgery 22 : 53-60, 2009.
 
8) Yokoyama O, Homma Y, Yamaguchi O : Imidafenacin, an antimuscarinic agent, improves nocturia and reduces nocturnal urine volume. Urology 82 : 515-520, 2013.
PubMed
9) Yokoyama O, Tsujimura A, Akino H, Segawa N, Tamada S, Oguchi N, Kitagawa Y, Tsuji H, Watanabe A, Inamoto T, Shimizu N, Fujiuchi Y, Katsuoka Y, Azuma H, Matsuda T, Namiki M, Uemura H, Okuyama A, Nonomura N, Fuse H, Nakatani T : Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment : A multi-centre, prospective, randomised study World J Urol 33 (5) : 659-667, 2015.
 
10) Sakakibara R, Tateno F, Yano M, Takahashi O, Sugiyama M, Ogata T, Haruta H, Kishi M, Tsuyusaki Y, Yamamoto T, Uchiyama T, Yamanishi T, Yamaguchi C : Imidafenacin on bladder and cognitive function in neurologic OAB patients. Clin Auton Res 23 : 189-195, 2013.
PubMed
11) Zaitsu M, Mikami K, Ishida N, and Takeuchi T : Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder : A Prospective, Open, Randomized, Parallel-Group Trial (the List Study). Advances in Urology : 854697, 2011.
PubMed
12) Yokoyama T, Koide T, Hara R, Fukumoto K, Miyaji Y, Nagai A : Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder : a prospective randomized controlled study. Urol Int 90 : 161-167, 2013.
PubMed
13) 山口脩, 本間之夫 : イミダフェナシン増量長期投与試験. 薬理と治療 37 : 909-930, 2009.
Medical*Online
14) 山口脩 : コハク酸ソリフェナシン長期投与試験. 薬理と治療 34 (Supl 36) : S69-S86, 2006.
 
P.1230 掲載の参考文献
1) Nakamori T, Maebuchi M, Okuda J et al : Behavioral evidence for beneficial effects of soy peptide supplementation on higher brain function in healthy young volunteers. Jpn Pharmacol Ther 41 : 457-464, 2013.
 
2) Maebuchi M, Kishi Y, Koikeda T et al : Soy peptide dietary supplementation increases serum dopamine level and improves cognitive dysfunction in subjects with mild cognitive impairment. Jpn Pharmacol Ther 41 : 67-74, 2013.
 
3) Maebuchi M, Samoto M, Kohno M et al : Improvement in the intestinal absorption of soy protein by enzymatic digestion to oligopeptide in healthy adult men. Food Sci Technol Res 13 : 45-53, 2007.
 
4) Nakanishi Y, Shirakawa S, Maebuchi M et al. Effects of soy protein intake in peptide form on delayed-onset muscle soreness induced by eccentric exercise. J Sport Sci and Osteo Ther 13 : 9-19, 2011.
 
5) Masuda K, Maebuchi M, Samoto M et al : Effect of soy-peptide intake on exercise-induced muscle damage. Jap J Clin Sports Med 15 : 228-235, 2007.
 
6) Esaki K, Kokido T, Ohomori T et al : Soy peptide ingestion increases neuroactive amino acids in the adult brain of wild-type and genetically engineered serine-deficient mice. J Nutr Food Sci 1 : 109, 2011.
 

【臨床報告】

P.1238 掲載の参考文献
1) 日本循環器学会 : 急性冠症候群の診療に関するガイドライン, 循環器疾患の診断と治療に関するガイドライン (2000-2001年度合同研究班報告)
 
2) 吉川勉 : 心筋梗塞の二次予防 : 慢性期薬物療法 : β遮断薬とCa拮抗薬. 新 目でみる循環器病シリーズ10 心筋梗塞. 吉野秀朗編, p286, メディカルビュー社, 東京, 2007.
 
3) Dargie HJ : Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction : the CAPRICORN randomized trial. Lancet 357 : 1385-1390, 2001.
PubMed
4) Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction : ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 12 : 57-66, 1986.
 
5) Hiroyuki Daida, Katsumi Miyauchi, Hisao Ogawa et al : Management and Two-Year Long-Term Clinical Outcome of Acute Coronary Syndrome in Japan : Prevention of Atherothrombotic Incidents Following Ischemic Coronary Attack (PACIFIC) Registry. Circ J 77 : 934-943, 2013.
PubMed
6) Junichi Yamaguchi, Hiroshi Kasanuki, Yasuhiro Ishii et al : Serum Creatinine on Admission Predicts Long-Term Mortality in Acute Myocardial Infarction Patients Undergoing Successful Primary Angioplasty Data From the Heart Institute of Japan Acute Myocardial Infarction (HIJAMI) Registry. Circ J 71 : 1354?1359, 2007.
 
7) The MIAMI Trial Research Group : Metoprolol in acute myocardial infarction (MIAMI). A randmised placebo-controlled international trial. Eur Heart J 6 : 199-226, 1985.
 
8) Zaret BL, Wackers FJT, Terrin ML et al : Value of radionuclide rest and exercise left ventricular ejection fraction in assessing survival of patients after thrombolytic therapy for acute myocardial infarction : results of thrombolysis in myocardial infarction (TIMI) phase 2 study. J Am Coll Cardiol 26 : 73-79, 1995.
 

【Diagnosis】

P.1246 掲載の参考文献
1) 山口健他 : ProGRP (ガストリン放出ペプチド前駆体). 日本臨牀 53 : 779-787, 1995.
 
2) 吉村徹他 : 全自動化学発光免疫測定装置を用いた血中ガストリン放出ペプチド前駆体 (ProGRP) 測定試薬 (ARCHITECT(R)・ProGRP)の開発と基礎的評価. 医学と薬学 62 (4) : 759-766, 2009.
 
3) 中村恵理那他 : ProGRP研究会からの報告, 1) 肺疾患におけるProGRP測定値の検討. JJCLA 36 (4) : 632, 2011.
 
4) 絹川秀樹他 : ProGRP研究会からの報告, 2) 小細胞肺癌マーカーProGRPの新たな基準値及びカットオフ値の評価. JJCLA 36 (4) : 632, 2011.
 
5) 譽田大仁他 : ProGRP研究会からの報告, 4) Pro-GRPに対する検体の採取及び取り扱いに関する検討. JJCLA 36 (4) : 632, 2011.
 
6) 池田徳幸他 : 全自動化学発光免疫測定装置ARCHITECT(R)アナライザーを用いた「アーキテクト(R)・ProGRP」の基礎的検討と検体安定性の検討. 医療と検査機器・試薬 33 (3) : 413-418, 2010.
Medical*Online
7) 宮越静代他 : アーキテクト(R)・ProGRP測定試薬の性能評価. 医学と薬学 63 : 809-815, 2010.
Medical*Online
8) Patel O, Dumesny C, Shulkes A et al : C-Terminal Fragments of the Gastrin-Releasing Peptide Precursor Stimulate Cell Proliferation via a Novel Receptor. Endocrinology 148 (3) : 1330-1339, 2006.
 
9) 大谷真澄他 : 血清と血漿におけるガストリン放出ペプチド前駆体 (ProGRP)の安定性についての検討. JJCLA 35 : 863-867, 2010.
 
10) Yoshimura T, Fujita K, Kawakami S et al : Stability of progastrin-releasing peptide in serum versus plasma. Tumour Biol 29 : 224-230, 2008.
 
11) 前川知子他 : 電気化学発光免疫測定法 (ECLIA法) を用いたガストリン放出ペプチド前駆体 (Pro-GRP) 検出試薬の評価. 医学と薬学 71 (9) : 1643-1653, 2014.
 
P.1259 掲載の参考文献
1) 藤瀬清隆, 大野典也, 桜井進他 : 人由来乳癌細胞の産生するレトロウィルス様粒子に対するモノクローナル抗体の作製. 日本ウィルス学会 第1回ヒト細胞研究会抄録集, 92-93, 1983.
 
2) R Mesa-Tejada, R.B Palakodety, J.A Leon et al : Immunocytochemical Distribution of a Breast Carcinoma Associated Glycoprotein Identified by Monoclonal Antibodies. American Journal of Pathology 1302 (2) : 305-314, 1988.
 
3) 渋谷智顕, 樫木良友, 山本悟他 : 新しい乳癌腫瘍マーカーBCA225の組織内局在に関する検討. 第7回腫瘍マーカー研究会記録, 309-312, 1987.
 
4) 隈元謙介, 神奈木玲児 : BCA225. 日本臨牀 広範囲血液・尿化学検査 免疫学的検査 第6版, 2005.
 
5) 成田達彦, 舟橋啓臣, 佐藤康幸他 : 乳癌における腫瘍マーカーCA15-3, BCA225, NCC-ST-439の血清及び免疫組織学的検討. 日本臨床外科医学会雑誌 53 (11) : 2580-2585, 1992.
 
6) 杉山和義, 河端誠, 射場敏明他 : 乳癌における新しい腫瘍マーカーBCA225の有用性の検討. 日本臨床外科医学会雑誌 51 (7) : 1380-1388, 1990.
 
7) 石和久, 川島徹, 谷尚志他 : 新しい乳癌腫瘍マーカーBCA225の臨床応用に関する検討 (第1報). 臨床病理 37 (3) : 301-305, 1989.
 
8) 石和久, 川島徹, 谷尚志他 : 新しい乳癌腫瘍マーカーBCA225の臨床応用に関する検討 (第2報). 臨床病理 23 (15) : 445-453, 1989.
 
9) 国立がん研究センターがん情報サービス http://ganjoho.jp/public/statistics/index.html 2015年5月21 日閲覧
 
10) 大倉久直, 石井勝, 高橋豊他 : 腫瘍マーカー臨床マニュアル, 医学書院, 東京, 1999.
 
11) D. W Tholen, K Linnet, M Kondratovich et al : Clinical and Laboratory Standards Institute : Protocols for Detection of Limits and Limits of Quantitation, Approved Guideline. : CLSI : document EP17-A.2004.
 
12) 石橋みどり : 非特異反応-イムノアッセイのピットフォール. 検査と技術 38 (10) : 778-782, 2010.
 
13) 杉山和義 : 疾患と検査値の推移 乳癌. 検査と技術 41 (5) : 387-393, 2013.
 
14) 宋瑩, 大出勝也 : 全自動臨床検査システムSTACIAにおける腫瘍マーカー (AFP, CA19-9, CEA) の基礎検討. 日本臨床検査自動化学会会誌 39 (4) : 612-612, 2014.
Medical*Online

【Cosmetic】

P.1272 掲載の参考文献
1) Matoltsy A. G, Downes A. M, Sweeney T. M : Studies of the epidermal water barrier. II. Investigation of the chemical nature of the water barrier. J Invest Dermatol 50 : 19-26, 1968.
 
2) Elias P. M : Lipids and the epidermal permeability barrier. Archives of dermatological research 270 : 95-117, 1981.
PubMed
3) Howitz, K. T, Bitterman K. J, Cohen H. Y, Lamming D. W, Lavu S, Wood J.G, Zipkin R. E, Chung P, Kisielewski A, Zhang L. L, Scherer B, Sinclair D. A : Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425 : 191-196, 2003.
PubMed
4) Tissenbaum H. A, Guarente L : Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410 : 227-230, 2001.
PubMed
5) Rogina B, Helfand S. L : Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci USA 101 : 15998-16003, 2004.
PubMed
6) Herranz D, Munoz-Martin M, Canamero M, Mulero F, Martinez-Pastor B, Fernandez-Capetillo O Serrano M : Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun 1 : 3, 2010.
PubMed
7) Inoue T, Hiratsuka M, Osaki M, Oshimura M : The molecular biology of mammalian SIRT proteins : SIRT2 in cell cycle regulation. Cell Cycle 6 : 1011-1018, 2007.
PubMed
8) Zhang Q, Zeng S. X, Zhang Y, Zhang Y, Ding D, Ye Q, Meroueh S. O, Lu H : A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p.53. EMBO molecular medicine 4 : 298-312, 2012.
 
9) Rieder S. A, Nagarkatti P, Nagarkatti M : Multiple anti-inflammatory pathways triggered by resveratrol lead to amelioration of staphylococcal enterotoxin B-induced lung injury. Br J Pharmacol 167 : 1244-1258, 2012.
PubMed
10) Das S, Das D. K : Anti-inflammatory responses of resveratrol. Inflammation & allergy drug targets 6 : 168-173, 2007.
PubMed
11) Bhatt J. K, Thomas S, Nanjan M. J : Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutrition research 32 : 537-541, 2012.
PubMed
12) Brasnyo P, Molnar G. A, Mohas M, Marko L, Laczy B, Cseh J, Mikolas E, Szijarto I. A, Merei A, Halmai R, Meszaros L. G, Sumegi B, Wittmann I : Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 106 : 383-389, 2011.
PubMed
13) Elliott P. J, Jirousek M : Sirtuins : novel targets for metabolic disease. Current opinion in investigational drugs 9 : 371-378, 2008.
PubMed
14) Kennedy D. O, Wightman E. L, Reay J. L, Lietz G, Okello E. J, Wilde A, Haskell C. F : Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans : a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr 91 : 1590-1597, 2010.
PubMed
15) Buonocore D, Lazzeretti A, Tocabens P, Nobile V, Cestone E, Santin G, Bottone M. G, Marzatico F : Resveratrol-procyanidin blend : nutraceutical and antiaging efficacy evaluated in a placebocontrolled, double-blind study. Clinical, cosmetic and investigational dermatology 5 : 159-165, 2012.
 
16) 岩井一郎, 傳田光洋, 宇田正紀 : 皮膚の測定・評価マニュアル集 技術情報協会, pp.72-15, 2003.
 
17) 抗老化機能評価専門委員会 : 新規効能取得のための抗シワ製品評価ガイドライン. 日本香粧品学会誌 30 : 316-332, 2006.
 
18) Ohguchi K, Itoh T, Akao Y, Inoue H, Nozawa Y, Ito M : SIRT1 modulates expression of matrix metalloproteinases in human dermal fibroblasts. The British journal of dermatology 163 : 689-694, 2010.
PubMed
19) Glenda H, Tania J. P : Estrogen and skin : The effects of estrogen, menopause, and hormone replacement therapy on the skin. J Amer Acad Dermatology 53 : 555-568, 2005.
 
20) Ashcroft G. S, Dodsworth J, van Boxtel E, Tarnuzzer R. W, Horan M. A, Schultz G. S, Ferguson M. W : Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nat Med 3 : 1209-1215, 1997.
PubMed
21) Gehm, B. D, McAndrews J. M, Chien P. Y, Jameson J. L : Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 94 : 14138-14143, 1997.
PubMed
22) Pozo-Guisado E, Lorenzo-Benayas M. J, Fernandez-Salguero P. M : Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism : relevance in cell proliferation. Int J Cancer 109 : 167-173, 2004.
PubMed
23) Rakici O, Kiziltepe U, Coskun B, Aslamaci S, Akar F : Effects of resveratrol on vascular tone and endothelial function of human saphenous vein and internal mammary artery. Int J Cardiol 105 : 209-215, 2005.
PubMed
24) Yonei Y, Yagi M, Ogura M, Sugimura H : Anti-Glycation Activity and Safety of Foods Containing Lingonberry Extract and Cherry Blossom Extract and Chewable Tablets Containing Citric Acid and Calcium-A Placebo-Controlled Randomized Single-Blind Parallel Group Comparative Study. Anti-Aging Medicine 10 : 21-35, 2013.
 

書評

最近チェックした商品履歴

Loading...